Abstract
2073 Background: IDH1 mutated glioblastoma (GB) has a better prognosis than IDH1 wildtype GB. Clinical trials for recurrent GB currently do not stratify patients (pts) based upon IDH status. It is not known if pts with IDH1 mutated GB on clinical trials are more likely to have a higher 6-month progression free survival (PFS6) or radiographic response (RR) rate. Methods: A retrospective review of GB pts treated at MD Anderson Cancer Center between 2006-2012 identified 330 pts enrolled in recurrent GB trials. 93 pts (28%) either had PFS6 or a complete or partial RR per RANO criteria. 49/93(53%) pts with PFS6 or a complete or partial RR were found to have tumor tissue available for IDH1 testing. A matched cohort of pts on the same recurrent GB clinical trials with tissue for IDH1 testing but no PFS6 or RR was identified based on the specific clinical trial, age and KPS. 49 pts were identified for comparison resulting in a total of 98 patients. Results: IDH1 status was obtained in 92 (94%) pts of which 17 (18...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
